I.LeeB.HoyleC.YuS.Lopez-CastejonG.LoweM.et al (2020)
Common adverse effects include: Gastrointestinal symptoms (nausea, vomiting, diarrhoea), which are very common and affect a substantial proportion of users, particularly during dose escalation Gallbladder disorders, including cholelithiasis, associated with rapid weight loss Warnings and precautions in UK SmPCs include: Acute pancreatitis: patients should be advised of characteristic symptoms (persistent severe abdominal pain) and treatment must be discontinued if pancreatitis is suspected Diabetic retinopathy complications: in patients with pre-existing diabetic retinopathy, rapid improvement in glucose control has been associated with temporary worsening
Pharmacological inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle
39 Although GLP-1RAs continue to be promising therapies for T2D, their long-term efficacy for weight loss after halting treatment should be further improved
The pharmacy leader highlighted that prior to ePA, such cases would have involved back-and-forth calls and likely a much later delivery
The response was uniformly dismissive